Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Newave Pharmaceutical Inc. manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 pending office actions represent the core of the company's current legal efforts at the USPTO. The focus on Biotechnology & Pharmaceuticals indicates a commitment to medical and drug-related innovation. Practitioners should note the technical diversity within this technology area.
The 5 pending office actions are spread across 2 distinct art units and 5 distinct examiners. With 5 distinct examiners involved, each of the 5 pending office actions is being handled by a different individual. This distribution means there is no overlap in examiner assignments, requiring a unique approach for each case. The involvement of 2 distinct art units indicates that the company's technology is being examined by specialized groups at the USPTO.
WILLIS, DOUGLAS M is the busiest examiner, responsible for 1 busiest examiner pending action. Since each of the 5 distinct examiners holds exactly 1 action, the workload is evenly spread across the portfolio. Practitioners must coordinate their efforts across 2 distinct art units to address the 5 pending office actions. This structure allows for a focused strategy within the 2 distinct art units while managing 5 distinct examiner relationships.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| FERGUSON, JALISA HOLMES | 1 | 61.1% | +43.8% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020980 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | ENGLISH, CONNOR KENNEDY | 50d overdue |
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | — |
| 18721999 | BCL-2 INHIBITORS | SCHMITT, MICHAEL J | — |
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | — |
| 18033481 | INHIBITORS OF BTK | FERGUSON, JALISA HOLMES | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798308 | INHIBITORS OF BTK AND MUTANTS THEREOF | WILLIS, DOUGLAS M | — | §112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18721999 | BCL-2 INHIBITORS | SCHMITT, MICHAEL J | — | Other | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18678175 | BCL-2 INHIBITORS | ANDERSON, REBECCA L | — | §101§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18033481 | INHIBITORS OF BTK | FERGUSON, JALISA HOLMES | 1626 | §112 | Final Rejection | — | Pending | Apr 24, 2023 |
| 18020980 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | 50d overdue | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial